Karamedica has developed a plasma treatment system to decontaminate chitosan, a biopolymer found in the shells of shrimps and crabs. Karamedica is currently developing a nanoparticle therapy for cerebral amyloid angiopathy. The firm's PIs are recongized experts in chitosan. Karamedicaâs driving goal is to expand medical and veterinary uses of biopolymer-based products, especially those containing chitosan, by developing novel decontamination processes like non-thermal plasmas. Karamedica also seeks to create innovative medical devices and drug delivery systems based on these biopolymers
